Evidence map›Paper›PMID 32934719›Full record

ArticleOncology letters2020

Pro-apoptotic activity of novel synthetic isoxazole derivatives exhibiting inhibitory activity against tumor cell growth

Ilaria Lampronti, Daniele Simoni, Riccardo Rondanin, Riccardo Baruchello, Chiara Scapoli, Alessia Finotti, Monica Borgatti, Chiara Tupini, Roberto Gambari

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition.Current drug discovery technologies · 2025
    Article
  3. Article
  4. Article
  5. New Oxazolo[5,4-International journal of molecular sciences · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ilaria LamprontiDepartment of Life Sciences and Biotechnology, Ferrara University, I-44121 Ferrara, Italy.
Daniele SimoniDepartment of Chemical and Pharmaceutical Sciences, Ferrara University, I-44121 Ferrara, Italy.
Riccardo RondaninDepartment of Chemical and Pharmaceutical Sciences, Ferrara University, I-44121 Ferrara, Italy.
Riccardo BaruchelloDepartment of Chemical and Pharmaceutical Sciences, Ferrara University, I-44121 Ferrara, Italy.
Chiara ScapoliDepartment of Life Sciences and Biotechnology, Ferrara University, I-44121 Ferrara, Italy.
Alessia FinottiDepartment of Life Sciences and Biotechnology, Ferrara University, I-44121 Ferrara, Italy.
Monica BorgattiDepartment of Life Sciences and Biotechnology, Ferrara University, I-44121 Ferrara, Italy.
Chiara TupiniDepartment of Life Sciences and Biotechnology, Ferrara University, I-44121 Ferrara, Italy.
Roberto GambariDepartment of Life Sciences and Biotechnology, Ferrara University, I-44121 Ferrara, Italy.
University of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to develop potential anticancer agents stimulating apoptosis, novel 3,4-isoxazolediamide and 4,5,6,7-tetrahydro-isoxazolo-[4,5-c]-pyridine derivatives have been synthetized. The original structures of geldanamycin and radicicol, which are known natural heat shock protein (HSP) inhibitors, were deeply modified because both of them exhibit several drawbacks, such as poor solubility, hepatotoxicity, intrinsic chemical instability or deprivation of the

Indexed as

apoptosiscancercaspasesglioblastomaheat shock protein inhibitorsK562 cellsT98G cellsU251-MG cells

Identifiers

PMID32934719
PMCPMC7471682
OpenAlexW3080986126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.